Unknown

Dataset Information

0

Posttransplant Diabetes Mellitus and Immunosuppression Selection in Older and Obese Kidney Recipients.


ABSTRACT:

Rationale & objective

Posttransplant diabetes mellitus (DM) after kidney transplantation increases morbidity and mortality, particularly in older and obese recipients. We aimed to examine the impact of immunosuppression selection on the risk of posttransplant DM among both older and obese kidney transplant recipients.

Study design

Retrospective database study.

Setting & participants

Kidney-only transplant recipients aged ≥18 years from 2005 to 2016 in the United States from US Renal Data System records, which integrate Organ Procurement and Transplantation Network/United Network for Organ Sharing records with Medicare billing claims.

Exposures

Various immunosuppression regimens in the first 3 months after transplant.

Outcomes

Development of DM >3 months-to-1 year posttransplant.

Analytical approach

We used multivariable Cox regression to compare the incidence of posttransplant DM by immunosuppression regimen with the reference regimen of thymoglobulin (TMG) or alemtuzumab (ALEM) with tacrolimus + mycophenolic acid + prednisone using inverse propensity weighting.

Results

12.7% of kidney transplant recipients developed posttransplant DM with higher incidences in older (≥55 years vs <55 years: 16.7% vs 10.1%) and obese (body mass index [BMI] ≥ 30 kg/m2 vs BMI < 30 kg/m2: 17.1% vs 10.9%) patients. The incidence of posttransplant DM was lower with steroid avoidance [TMG/ALEM + no prednisone (8.4%) and IL2rAb + no prednisone (9.7%)] than TMG/ALEM with triple therapy (13.1%). After adjustment for donor and recipient characteristics, TMG/ALEM with steroid avoidance was beneficial for all groups [age < 55 years: adjusted HR (aHR), 0.63 (95% confidence interval [CI], 0.54-0.72); age ≥ 55 years: aHR, 0.69 (95% CI, 0.60-0.79); BMI < 30 kg/m2: aHR, 0.69 (95% CI, 0.60-0.78); BMI ≥ 30 kg/m2: aHR, 0.67 (95% CI, 0.57-0.79)]. However, IL2rAb with steroid avoidance was beneficial only for older patients (aHR, 0.76; 95% CI, 0.58-0.99) and for those with BMI < 30 kg/m2 (aHR, 0.63; 95% CI, 0.46-0.87).

Limitations

Retrospective study and lacked data on immunosuppression levels.

Conclusions

The beneficial impact of steroid avoidance using tacrolimus on posttransplant DM appears to differ by patient age and induction regimen.

SUBMITTER: Axelrod DA 

PROVIDER: S-EPMC8767140 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8185023 | biostudies-literature
| S-EPMC6535897 | biostudies-literature
| S-EPMC6223248 | biostudies-literature
| S-EPMC8182337 | biostudies-literature
| S-EPMC5051963 | biostudies-literature
| S-EPMC8670588 | biostudies-literature
| S-EPMC3220839 | biostudies-other
| S-EPMC4426259 | biostudies-literature
| S-EPMC5338704 | biostudies-other
| S-EPMC5829348 | biostudies-literature